Story
Travere Therapeutics Taps Amicus Veteran as New CEO; Shares Dip on Transition News
Summary
Travere Therapeutics announced that Eric Dube will step down as CEO, to be succeeded by former Amicus Therapeutics CEO Bradley L. Campbell on December 1, 2026. The company's shares fell modestly in after-hours trading following the news.
Travere Therapeutics (NASDAQ: TVTX) announced a planned leadership transition on Monday, causing its shares to fall in after-hours trading. The biopharmaceutical company named Bradley L. Campbell, former CEO of Amicus Therapeutics, as its next president and chief executive officer, succeeding Eric Dube, Ph.D., who is stepping down for personal health and family reasons.
The Leadership Handover
The company confirmed the transition will be effective December 1, 2026. Dr. Dube will continue in his role as president and CEO until that date to ensure a smooth handover. Following the transition, he will remain with the company as an executive advisor through February 15, 2027.
Gary Lyons, chairman of Travere's Board of Directors, stated that the board conducted a comprehensive search and selected Campbell for his scientific, commercial, and operational expertise. The board highlighted his track record in scaling rare disease therapies and advancing clinical pipelines as key qualifications for leading Travere's next phase.
Incoming and Outgoing CEO Profiles
AdBradley L. Campbell brings over 25 years of experience in the biopharmaceutical industry. He most recently served as president and CEO of Amicus Therapeutics, where he spent nearly 20 years in roles of increasing responsibility. During his tenure, Amicus grew from a single-product company into a global rare disease organization. His prior experience includes roles at Genzyme and Bristol-Myers Squibb.
Dr. Dube has served as Travere's CEO since January 2019. During his leadership, the company secured regulatory approvals in IgA nephropathy and focal segmental glomerulosclerosis (FSGS) and expanded its pipeline.
Market Reaction
Following the announcement, shares of Travere Therapeutics fell by as much as 2.3% in after-hours trading on Monday. Leadership changes, even when planned, can create short-term uncertainty among investors, often resulting in modest stock price fluctuations as the market assesses the new executive's potential impact on company strategy and performance.
Read next
More on Stocks
Nyxoah Shares Fall 2% After CFO John Landry Announces Departure
The medical technology company announced the departure of its Chief Financial Officer, effective October 2, but moved to reassure investors by reaffirming its full-year 2026 financial guidance.
Vicor Shares Rise After Company Doubles Q3 Revenue Growth Forecast
Vicor Corporation raised its third-quarter revenue guidance, citing new licensing royalties for its power delivery technology, which sent its stock up 6% in after-hours trading.
ExxonMobil Stock Slides as Oil Prices Retreat on Mideast Diplomatic Hopes
Shares of the energy giant fell more than 3% as crude oil prices dropped sharply on signs of easing geopolitical tensions, while a neutral analyst rating added to the selling pressure.
American Savings Bank Finalizes Upsized IPO at $16 Per Share
Hawaii-based American Savings Bank's existing stockholders sold over 9.2 million shares in a secondary offering, including the full exercise of the underwriters' over-allotment option. The bank itself did not receive any proceeds from the sale.